OSA vs. NURO, INBS, VVOS, PSTV, AVGR, BTCY, VAPO, PETV, TMDIF, and VERO
Should you be buying ProSomnus stock or one of its competitors? The main competitors of ProSomnus include NeuroMetrix (NURO), Intelligent Bio Solutions (INBS), Vivos Therapeutics (VVOS), Plus Therapeutics (PSTV), Avinger (AVGR), Biotricity (BTCY), Vapotherm (VAPO), PetVivo (PETV), Titan Medical (TMDIF), and Venus Concept (VERO). These companies are all part of the "surgical & medical instruments" industry.
NeuroMetrix (NASDAQ:NURO) and ProSomnus (NASDAQ:OSA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations, community ranking and media sentiment.
19.4% of NeuroMetrix shares are owned by institutional investors. Comparatively, 70.0% of ProSomnus shares are owned by institutional investors. 4.4% of NeuroMetrix shares are owned by company insiders. Comparatively, 7.7% of ProSomnus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
ProSomnus has a consensus target price of $2.33, indicating a potential upside of 7,366.67%. Given NeuroMetrix's higher possible upside, analysts clearly believe ProSomnus is more favorable than NeuroMetrix.
NeuroMetrix received 280 more outperform votes than ProSomnus when rated by MarketBeat users. However, 80.00% of users gave ProSomnus an outperform vote while only 61.74% of users gave NeuroMetrix an outperform vote.
NeuroMetrix has higher earnings, but lower revenue than ProSomnus. NeuroMetrix is trading at a lower price-to-earnings ratio than ProSomnus, indicating that it is currently the more affordable of the two stocks.
ProSomnus has a net margin of -87.14% compared to ProSomnus' net margin of -151.51%. NeuroMetrix's return on equity of 0.00% beat ProSomnus' return on equity.
In the previous week, NeuroMetrix had 4 more articles in the media than ProSomnus. MarketBeat recorded 4 mentions for NeuroMetrix and 0 mentions for ProSomnus. NeuroMetrix's average media sentiment score of 0.00 beat ProSomnus' score of -0.24 indicating that ProSomnus is being referred to more favorably in the news media.
NeuroMetrix has a beta of 2.28, meaning that its stock price is 128% more volatile than the S&P 500. Comparatively, ProSomnus has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500.
Summary
ProSomnus beats NeuroMetrix on 11 of the 17 factors compared between the two stocks.
Get ProSomnus News Delivered to You Automatically
Sign up to receive the latest news and ratings for OSA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ProSomnus Competitors List
Related Companies and Tools
